Biopharma Industry: Insights from BioSpace Senior Editor Annalee Armstrong

What It Covers

BioSpace Senior Editor Annalee Armstrong joins Biotech Bulls & Breakthroughs on July 30, 2025 to assess the biopharma landscape, covering neurodegenerative disease pipelines, GLP-1 drug safety gaps, FDA regulatory instability under the Trump administration, PDUFA date delays, and AI-aided drug discovery's unproven track record.

Key Questions Answered

• •Neurodegenerative pipeline opportunity: Alzheimer's drug development is undervalued relative to its activity level. Roche returned with early brain shuttle data after a prior clinical failure, and Eli Lilly's follow-on candidate Remternitog has a major readout scheduled for 2026. Investors focused solely on GLP-1 may be overlooking this pipeline-rich therapeutic area.
• •GLP-1 safety gap as investment signal: Next-generation GLP-1 drugs must address gastrointestinal side effects, bone density loss, and muscle mass reduction alongside fat loss. Companies like Viking Therapeutics are targeting these specific deficits. Investors should identify biotechs developing complementary therapies that treat GLP-1-induced muscle or bone loss as a distinct, high-demand category.
• •Merck's acquisition posture signals oncology opportunity: With Keytruda facing patent expiration, Merck signaled on its July 2025 earnings call that it is actively seeking additional acquisitions beyond its $10 billion Verona Pharma COPD deal. Biotechs holding oncology assets with active partnership discussions represent elevated buyout targets in the near term.
• •FDA instability creating material PDUFA risk: The unexpected removal of Vinay Prasad from CBER after just three months, combined with ongoing agency layoffs, is already producing PDUFA date delays. Traders and investors who rely on PDUFA calendars for catalyst timing should build wider uncertainty windows into their planning, as previously fixed decision dates are becoming unreliable.
• •AI drug discovery lacks clinical validation: Despite heavy capital inflows, AI-aided drug discovery has not produced faster or more successful clinical outcomes than traditional methods. The few AI-originated candidates reaching clinical trials show no superior success rates. Sanofi's approach of integrating AI across administrative and operational functions, not just discovery, is presented as a more grounded near-term strategy.